PeptideSearch

Semax

Tested in people

Get notified when the evidence changes.

It has been tested in people, but it is not an approved medicine. The studies are usually small.

Compiled and reviewed by the PeptideSearch Editorial Team · Status checked 2026-07-24

Also called ACTH 4-10 analogue / Met-Glu-His-Phe-Pro-Gly-Pro / N-Acetyl Semax

Developed in Russia and used there for stroke recovery. Little research exists outside Russia.

Official status: Recommended, pending FDA rulemaking · Checked 2026-07-24

Can a doctor prescribe this?

Small pharmacy (503A)
Reviewed by FDA — see timeline
Large outsourcing facility (503B)
Never put forward to FDA

An FDA advisory panel voted 8-5 in favor in July 2026, but the rule isn't final. That usually takes a year or more.

503A is a pharmacy making a single prescription for one patient. 503B is a facility making batches. They are governed by separate lists. Where a category is shown, it is a position on the FDA's list of substances that have been put forward and are still being worked through — not the final list, which is set by rulemaking. Category 1 means the FDA does not plan to act against a pharmacy that makes it while the review runs.

Lab suppliers we list: 16

Doses used in research

Taken word for word from the studies and trials listed on this page. This is not a recommendation and not a dose for anyone to take.

Spot an error? corrections@peptidesearch.org

What has happened so far

  1. 24 July 2026503A

    FDA proposed that Semax NOT be included on the 503A Bulks List.

    FDA briefing documentnot yet verified against primary source

  2. 16 April 2026503A

    FDA published a Federal Register notice announcing a Pharmacy Compounding Advisory Committee meeting for July 23-24, 2026 at the White Oak campus, to consider seven peptides for the 503A Bulks List.

    Federal Registernot yet verified against primary source

We'll email you when a new study, trial or status change lands for Semax. Unsubscribe in one click.